BACARDI-LIMITED
Family-owned Bacardi Limited has been doing the right thing for its people, its community and the planet more than 158 years. Today, the company released its fiscal year 2019 Good Spirited Corporate Responsibility (CR) Report to provide open and transparent communications in how it’s championing commitments within its CR pillars of marketplace , people , environment , responsible sourcing , and philanthropy and community investment . From responsible drinking efforts, to driving a positive and diverse culture, to hurricane disaster relief and reducing the impact on natural resources, the Good Spirited Corporate Responsibility Report outlines progress in fiscal year 2019, alongside commitments for the future. This marks the 12th annual CR report issued by privately-held Bacardi Limited.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005465/en/
“Being family-owned for seven generations allows us to stay true to our values of being fearless to innovate, behaving like family to each other and our communities, and exhibiting founders mentality in always doing the right thing -- particularly towards making the world a more sustainable, safe and transparent place,” says Rick Wilson, Senior Vice President of Corporate Responsibility at Bacardi. “It’s extremely gratifying to see us achieve key milestones, in some cases ahead of time, and to continuously pursue new goals and set higher standards for the future.”
The report outlines the overall marketplace for spirits and addresses the responsibility Bacardi has in promoting responsible drinking practices and targeting our marketing only to legal age drinkers. With the evolution of digital marketing, the company has doubled down efforts to enforce safeguards to limit minors from seeing alcohol marketing online. Bacardi has achieved 79% compliance in establishing these safeguards with an aim to be 100% compliant by 2020. Bacardi has also been an early mover in the space of nutrition transparency, with the launch of a Bacardi nutrition website in key markets giving consumers more information about what they’re drinking including calories and allergens.
The vibrant, warm and entrepreneurial culture at Bacardi is reflected in the exceptional employee engagement with the global internal survey showing 89% of employees saying they are “proud to work for the company.” External perception of the company is also positive as Bacardi Limited was named among the most reputable companies in the world as part of the annual Global RepTrak® 100 list compiled by the Reputation Institute (RI) and published in Forbes. Ranked at #87, Bacardi Limited climbed two spots and has made the annual global list seven consecutive times.
Bacardi believes in the inherent value that can be created when you bring together a diverse and inclusive community and workplace. Helping female talent at Bacardi, and within our community, is among the many causes championed by the company through its Global Reflections program. The company has made considerable headway with women making up 44% of North America and 40% of Europe – which represent the two largest regions of the business. In addition, 37% of the leadership positions in the company were held by women in fiscal year 2019 and the company continues to work towards narrowing the gender gap.
Bacardi continues to push the boundaries with aspirations to be the world’s most environmentally responsible global spirits company. Finding a second life for all waste is a priority and the company’s production facilities have achieved 99.6% of waste diversion. Despite increases in production, the company has been able to reduce greenhouse gas emissions from operations by 20% and cut water consumption by almost 10% through efficiencies in assets utilization. It is also committed to the long-term sustainability and responsible sourcing of sugarcane, agave, wheat, botanicals, and other natural resources needed to craft its world-class premium products. Already 98.4% of the sugarcane-derived products used in BACARDÍ® rums are sourced from suppliers certified by Bonsucro, with the goal of reaching 100% by the end of fiscal year 2020, three years ahead of initial targets. The company also achieved ECOCERT certification for 50% of botanicals for BOMBAY SAPPHIRE® gin with a goal to certify 100% of the botanicals in the coming year. With an eye for the future and always pushing to do greater good, Bacardi has defined a long-term plan to reduce greenhouse gas emissions by 20% and water consumption by 25% by fiscal year 2024.
Going beyond the company to care for the community is part of the DNA at Bacardi since its inception in 1862. Bacardi, together with Mercy Corp, continues to support the long-term recovery efforts in Puerto Rico, where BACARDÍ rum is produced, after devastation from Hurricanes Maria and Irma in 2017, providing habitat rehabilitation, financial grants, business training, and marketing support to 243 businesses on the island.
To read more about Corporate Responsibility within Bacardi, check out the complete FY19 Corporate Responsibility Report, which encompasses April 1, 2018 – March 31, 2019, online https://www.bacardilimited.com/corporate-responsibility/ .
About Bacardi Limited
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka.
Founded more than 158 years ago, in Santiago de Cuba on February 4, 1862, family-owned Bacardi currently employs more than 7,000, operates more than 20 production facilities, including bottling, distilling and manufacturing sites in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Instagram , LinkedIn and Twitter .
Enjoy Responsibly.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200213005465/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
